Inovio Pharmaceuticals, Inc.INONASDAQ
LOADING
|||
INO Revenue Growth (YoY Quarterly)•+0.00%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | +13.97% | +0.00% | -100.00% | +0.00% |
| Gross Profit Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +25.71% | +19.16% | +16.61% | +42.77% | +85.39% |
| Weighted Average Shares Diluted Growth | +25.71% | +19.16% | +16.61% | +42.77% | +85.39% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -13.12% | -50.15% | -48.64% | -52.62% | -47.46% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -44.56% | -33.78% | -32.41% | -49.00% | -35.19% |
| Book Value per Share Growth | -57.66% | -51.01% | -53.46% | -79.34% | +0.00% |
| Debt Growth | -58.24% | -60.72% | -16.06% | -17.89% | -19.49% |
| R&D Expense Growth | +20.84% | -25.31% | -23.06% | -38.65% | -28.83% |
| SG&A Expenses Growth | -13.21% | -32.21% | -14.63% | +91210.05% | -8.55% |
1 / 4